Low-Dose Aspirin for Primary Prevention of Cardiovascular Disease

ABSTRACT

Progressive atherosclerosis followed by plaque rupture is the leading cause of acute cardiovascular events. Inhibition of platelet aggregation by acetylsalicylic acid (aspirin) reduces recurrent cardiovascular events in secondary prevention trials. By extracting data from available randomized trials that examined aspirin prevention in persons without previously known cardiovascular disease, we evaluated the use of aspirin as a primary prevention measure. Using the raw data presented in the source publication on death, fatal and nonfatal myocardial infarctions, and cerebrovascular accidents, all relative and absolute risk reductions were recalculated with confidence intervals. In healthy men above 45 years of age, men with an increased cardiovascular risk profile, and persons with diabetes mellitus or hypertension, the use of aspirin reduces the incidence of myocardial infarction and has a neutral effect on cerebrovascular events. The protective effect of aspirin is apparently most prominent in those persons with an increased risk of manifest atherosclerotic vascular disease. Notwithstanding these results, for each patient it remains essential to balance the cardiovascular risk profile against the small increased risk of bleeding complications when prescribing aspirin.

KEYWORDS

Aspirin - primary prevention - cardiovascular disease

REFERENCES

• 1 Craven L L. Acetylic acid: possible preventive of coronary thrombosis.  Ann West Med Surg . 1950;  4 95-99
• 2 Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.  Br Med J . 1994;  308 81-106
• 3 Rosendaal F R, Algra A. 20,000 kg aspirin and 45 pages.  Br Med J . 1994;  138 996-1000
• 4 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  Br Med J . 2002;  324 71-86
• 5 Fuster V, Badimon L, Badimon J J, Chesebro J H. The pathogenesis of coronary artery disease and the acute coronary syndromes, II.  N Engl J Med . 1992;  326 310-318
• 6 Peto R, Gray R, Collins R. Randomised trial of prophylactic daily aspirin in British male doctors.  Br Med J . 1988;  296 313-316
• 7 Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study.  N Engl J Med . 1989;  321 129-135
• 8 The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk.  Lancet . 1998;  351 233-241
• 9 Hansson L, Zanchetti A, Carruthers S G. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.  Lancet . 1998;  351 1755-1762
• 10 de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project.  Lancet . 2001;  357 89-95
• 11 ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14.  JAMA . 1992;  268 1292-1300
• 12 Hart R G, Halperin J L, McBride R, Benavente O, Man-Son-Hing M, Kronmal R A. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses.  Arch Neurol . 2000;  57 326-332
• 13 Hebert P R, Hennekens C H. An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease.  Arch Intern Med . 2000;  160 3123-3127
• 14 Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force.  Ann Intern Med . 2002;  136 161-172
• 15 Kjeldsen S E, Kolloch R E, Leonetti G. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study.  Hypertension Optimal Treatment. J Hypertens . 2000;  18 629-642
• 16 Meade T W, Brennan P J. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial.  Br Med J . 2000;  321 13-17
• 17 Roderick P J, Wilkes H C, Meade T W. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials.  Br J Clin Pharmacol . 1993;  35 219-226
• 18 Weil J, Colin-Jones D, Langman M. Prophylactic aspirin and risk of peptic ulcer bleeding.  Br Med J . 1995;  310 827-830
• 19 Manson J E, Stampfer M J, Colditz G A. A prospective study of aspirin use and primary prevention of cardiovascular disease in women.  JAMA . 1991;  266 521-527
• 20 Kronmal R A, Hart R G, Manolio T A, Talbert R L, Beauchamp N J, Newman A. Aspirin use and incident stroke in the cardiovascular health study. CHS Collaborative Research Group.  Stroke . 1998;  29 887-894
• 21 Iso H, Hennekens C H, Stampfer M J. Prospective study of aspirin use and risk of stroke in women.  Stroke . 1999;  30 1764-1771
• 22 He J, Whelton P K, Vu B, Klag M J. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials.  JAMA . 1998;  280 1930-1935
• 23 Sanmuganathan P S, Ghahramani P, Jackson P R, Wallis E J, Ramsay L E. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.  Heart . 2001;  85 265-271
• 24 Lauer M S. Clinical practice. Aspirin for primary prevention of coronary events.  N Engl J Med . 2002;  346 1468-1474